Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
STRO · against 170 other Healthcare companies of similar size
Ranked #79 of 171 · scores higher than 39% of peers
Bars: peers in each 10-point band of the valuation score37 peers with a valuation score of 30–39, including STRO · Click a bar to see the companies
Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | STRO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 157 reported | -182.6% | -9.7% | 3% | 30% | |
| EBITDA yieldHigher is better · 181 reported | -10832.3% | 0.4% | 1% | 50% | |
| Free cash flow yieldHigher is better · 115 reported | -92.3% | -16.8% | 6% | 20% | |
| Book yieldHigher is better · 161 reported | -65.5% | 70.2% | 3% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 79 | 276M USD | 33 | 46 | |
| 79 | 149M USD | 33 | ||
| 79 | 191M USD | 33 | 38 | |
| 79 | 165M USD | 33 | 50 | |
| 79 | 158M USD | 33 | 14 | |
| 79 | 142M USD | 33 | 45 | |
| 79 | 89M USD | 33 | 31 | |
| 79 | 184M USD | 33 | 33 | |
| 79 | 186M USD | 33 | 52 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score